Login to Your Account



FDA Response Letter Seen As Positive Sign For MedImmune

By Aaron Lorenzo


Friday, January 31, 2003
A complete response letter from the FDA regarding FluMist has elicited a positive reaction at MedImmune Inc., which also reported record revenue as part of its fourth-quarter and year-end earnings. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription